公开(公告)号：US20240226034A1

公开(公告)日：2024-07-11

申请号：US18557258

申请日：2022-04-27

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Robert Brosnan

IPC分类号： A61K31/122 ,  A61K9/00 ,  A61K9/107 ,  A61K31/603 ,  A61K47/40 ,  A61P23/00

CPC分类号： A61K31/122 ,  A61K9/0019 ,  A61K9/107 ,  A61K31/603 ,  A61K47/40 ,  A61P23/00

摘要： Provided herein are compositions for inducing anesthesia in a subject, where the compositions include at least one compound that is either a terpenoid or a salicylate. The provided compositions are particularly useful for applications where the subject is a livestock animal used for meat or milk production, as the anesthetic agents have no toxic effects on food byproducts. The compositions provide further advantages for applications where the subject is a human undergoing a medical procedure. Also provided are methods for using the disclosed compositions and compounds.

公开(公告)号：US11992560B2

公开(公告)日：2024-05-28

申请号：US17251601

申请日：2018-06-14

申请人： ALMA MATER STUDIORUM—UNIVERSITÀ DI BOLOGNA

发明人： Laura Calza ,  Luciana Giardino ,  Maria Letizia Focarete ,  Chiara Gualandi ,  Maria-Laura Bolognesi ,  Nadia Passerini ,  Giampiero Pagliuca ,  Teresa Gazzotti ,  Elisa Zironi

IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K31/12 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/5415 ,  A61K31/5575 ,  A61K31/603 ,  A61K31/704 ,  A61P25/28

CPC分类号： A61K9/70 ,  A61K9/0024 ,  A61K31/12 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/5415 ,  A61K31/5575 ,  A61K31/603 ,  A61K31/704 ,  A61P25/28

摘要： The present invention relates to electro spun fibers for a local release in the central nervous system of an anti-inflammatory and a promyelinating agent over a defined time-window, in order to limit secondary neurodegeneration triggered by the glutamate release and supported by on-going inflammation. The combined treatment aimed to reduce inflammation and improve remyelination in the very early stage of the pathology improving the chronic clinical outcome of the lesion. In particular the present invention relates to electrospun polymeric fibers, wherein said fibers are loaded with 3,3,5-Triiodo-L-thyronine (T3) and Ibuprofen.

公开(公告)号：US20240075052A1

公开(公告)日：2024-03-07

申请号：US18476506

申请日：2023-09-28

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Jared A. Gollob

IPC分类号： A61K31/7105 ,  A61K9/00 ,  A61K9/107 ,  A61K31/07 ,  A61K31/135 ,  A61K31/167 ,  A61K31/341 ,  A61K31/423 ,  A61K31/426 ,  A61K31/445 ,  A61K31/495 ,  A61K31/573 ,  A61K31/603 ,  A61P25/28 ,  C12N15/113

CPC分类号： A61K31/7105 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/07 ,  A61K31/135 ,  A61K31/167 ,  A61K31/341 ,  A61K31/423 ,  A61K31/426 ,  A61K31/445 ,  A61K31/495 ,  A61K31/573 ,  A61K31/603 ,  A61P25/28 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2320/31 ,  C12N2320/35

摘要： Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

公开(公告)号：US20210236520A1

公开(公告)日：2021-08-05

申请号：US17237361

申请日：2021-04-22

申请人： Aurin Biotech Inc.

发明人： Patrick L. McGeer ,  Moonhee Lee ,  Krista Kennedy ,  Edith G. McGeer ,  Douglas N. Bell

IPC分类号： A61K31/616 ,  A61K31/603 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08

摘要： Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof.

公开(公告)号：US10786473B2

公开(公告)日：2020-09-29

申请号：US16569055

申请日：2019-09-12

申请人： SOM INNOVATION BIOTECH, S.L.

发明人： Marc Centellas Casado ,  Raúl Insa Boronat ,  Nuria Reig Bolaño ,  Núria Gavaldà Batalla

IPC分类号： A61K31/165 ,  A61K31/12 ,  A61K31/198 ,  A61K45/06 ,  A61K31/353 ,  A61K31/603 ,  A61K31/423 ,  A61K31/192

摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

公开(公告)号：US20190350907A1

公开(公告)日：2019-11-21

申请号：US16478520

申请日：2018-01-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE RENNES 1 ,  UNIVERSITÉ DE BORDEAUX ,  INSTITUT BERGONIÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CHU DE BORDEAUX

发明人： Patrick LEGEMBRE ,  Pierre VACHER ,  Amanda POISSONNIER ,  Patrick BLANCO

IPC分类号： A61K31/427 ,  A61K31/603 ,  A61K31/085 ,  A61K31/4439 ,  A61K31/704

摘要： The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLCγ1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin. Particularly, the method of the invention find use in the treatment of cancer such as triple negative breast cancer, autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

公开(公告)号：US10258592B2

公开(公告)日：2019-04-16

申请号：US15658730

申请日：2017-07-25

申请人： Biosuccess Biotech Co., Ltd.

发明人： Hung-Fong Chen ,  Zheng Tao Han

IPC分类号： A61K31/23 ,  A61K31/21 ,  A61K31/216 ,  A61K31/235 ,  A61K31/225 ,  A61K45/06 ,  A61K31/573 ,  A61K31/603 ,  A61K31/22 ,  A61K31/381 ,  A61K31/55

摘要： Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

公开(公告)号：US10159655B2

公开(公告)日：2018-12-25

申请号：US14960756

申请日：2015-12-07

申请人： Kao Corporation

发明人： Aya Kato ,  Naoko Saito ,  Michiaki Inoue ,  Kayoko Nomizu

IPC分类号： A61K31/121 ,  A61K31/603 ,  A61K31/045 ,  A61K31/05 ,  A61K31/11 ,  A61K31/12 ,  A61K31/09 ,  A61K31/365 ,  A61K31/122 ,  A61K31/075 ,  C07D241/12

摘要： Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

公开(公告)号：US20180207180A1

公开(公告)日：2018-07-26

申请号：US15411438

申请日：2017-01-20

申请人： Aurin Biotech Inc.

发明人： Patrick L. McGeer ,  Moonhee Lee ,  Krista Kennedy ,  Edith G. McGeer ,  Douglas N. Bell

IPC分类号： A61K31/616 ,  A61K31/603 ,  A61K9/00

CPC分类号： A61K31/616 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/08 ,  A61K31/603

摘要： Methods of treating a condition resulting in nociceptive pain are provided. The method includes the step of administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of diacetyl salicylic acid (DAS), aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), and/or a combination thereof.

公开(公告)号：US20170304243A1

公开(公告)日：2017-10-26

申请号：US15448054

申请日：2017-03-02

申请人： SOM INNOVATION BIOTECH, S.L.

发明人： Marc Centellas Casado ,  Raúl Insa Boronat ,  Nuria Reig Bolano ,  Núria Gavaldà Batalla

IPC分类号： A61K31/198 ,  A61K31/603 ,  A61K31/423 ,  A61K31/353 ,  A61K31/192 ,  A61K45/06 ,  A61K31/12

CPC分类号： A61K31/198 ,  A61K31/12 ,  A61K31/192 ,  A61K31/353 ,  A61K31/423 ,  A61K31/603 ,  A61K45/06 ,  A61K2300/00

摘要： It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.